Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 11/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6267145 | 0.79 | SMN1; SMN2 (0.60) | LMNAALDH1A1KMT2A | |
| SCHEMBL12125914 | 0.76 | NOTUM (0.44) | LMNAALDH1A1HSD11B1TP53 | |
| SCHEMBL27780939 | 0.76 | ALDH1A1 (0.50) | LMNAALDH1A1KMT2APOLB | |
| SCHEMBL732932 | 0.75 | LMNA (0.71) | LMNAALDH1A1HSD11B1GAAMEN1 | |
| SCHEMBL7436813 | 0.75 | AKR1C3 (0.50) | ALDH1A1 | |
| SCHEMBL1385963 | 0.74 | KMT2A (0.43) | LMNAALDH1A1GAAKMT2APOLB | |
| SCHEMBL26673580 | 0.73 | ALDH1A1 (0.49) | LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL13036468 | 0.73 | HSD11B1 (0.75) | LMNAALDH1A1HSD11B1GAAMEN1 | |
| SCHEMBL12169351 | 0.73 | HSD11B1 (0.75) | LMNAALDH1A1HSD11B1GAAMEN1 | |
| SCHEMBL24782290 | 0.73 | KMT2A (0.57) | LMNAALDH1A1GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404690-B2 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2013-03-26 | — | — | US | disclosed |
| EP-1592389-B1 | PIPERAZINE-2-CARBOXAMIDE DERIVATIVES | SERONO LAB (CH) | 2009-04-22 | — | — | EP | disclosed |
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | P2RX5, P2RX2, NPY5R | LMNA 976/4885ALDH1A1 610/4885HSD11B1 3490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.